Condition: Bladder Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with pembrolizumab. The goals of this study are to learn about: * The safety of the study treatment when given with standard treatment and if people tolerate it * The number of people who have the cancer respond (cancer gets smaller or goes away) with the new study treatment when given with standard treatment.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| UCSF Medical Center at Mission Bay ( Site 5044) | San Francisco, California, United States | Recruiting |
| University of Chicago Medical Center ( Site 5037) | Chicago, Illinois, United States | Recruiting |
| Cleveland Clinic Taussig Cancer ( Site 5036) | Cleveland, Ohio, United States | Recruiting |
| Huntsman Cancer Institute ( Site 5041) | Salt Lake City, Utah, United States | Recruiting |
| FALP ( Site 5151) | Santiago, Region M. de Santiago, Chile | Recruiting |
| CHU de Bordeaux Hop St ANDRE ( Site 5607) | Bordeaux, Gironde, France | Recruiting |
| Rambam Health Care Campus ( Site 5501) | Haifa, Israel | Recruiting |
| Rabin Medical Center ( Site 5504) | Petah Tikva, Israel | Recruiting |
| Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 5302) | Amsterdam, North Holland, Netherlands | Recruiting |
| Erasmus MC ( Site 5303) | Rotterdam, South Holland, Netherlands | Recruiting |
| Severance Hospital, Yonsei University Health System ( Site 5903) | Seoul, South Korea | Recruiting |
| Asan Medical Center ( Site 5901) | Seoul, South Korea | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07232602